Home / GU oncology / Bladder / urothelial / Neoadjuvant MIBC

Bladder / urothelial → Neoadjuvant muscle-invasive bladder cancer

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — treatment is cystectomy-anchored; perioperative strategies must be distinguished from adjuvant-only evidence

Who this applies to

Population	Direct-evidence boundary	Decision boundary
Resectable MIBC planned for radical cystectomy and pelvic lymph-node dissection	Confirm cT/cN stage, histology, obstruction and drainage needs, renal function, hearing, neuropathy, performance status, and surgical candidacy⁵⁶.	Reassess cisplatin eligibility after relief of tumor-related obstruction when feasible⁵⁶.
Cisplatin-eligible MIBC	NIAGARA and EV-304 evaluated distinct perioperative sequences²³.	Do not substitute adjuvant-only results for a preoperative strategy⁵⁶.
Cisplatin-ineligible or declining cisplatin	EV-303 evaluated perioperative EV plus pembrolizumab¹.	Not direct evidence for unresectable/metastatic disease or bladder preservation¹⁵.

Standard options

Clinical context	Option	Key inclusion	Typical course
Cisplatin-eligible, resectable MIBC	Perioperative durvalumab plus gemcitabine/cisplatin³	NIAGARA-type eligibility³.	Neoadjuvant durvalumab plus GC ×4 → cystectomy → adjuvant durvalumab ×8³.
Cisplatin-eligible, resectable MIBC	Perioperative EV plus pembrolizumab²	EV-304-type eligibility².	Neoadjuvant EV plus pembrolizumab ×4 → cystectomy → adjuvant EV plus pembrolizumab².
Cisplatin-ineligible or declining, resectable MIBC	Perioperative EV plus pembrolizumab¹	EV-303-type eligibility¹.	Neoadjuvant EV plus pembrolizumab ×3 → cystectomy → adjuvant EV plus pembrolizumab¹.
Not eligible for the above	Multidisciplinary cystectomy or bladder-preservation pathway⁵⁷	Need a separate evidence-based pathway⁵⁷.	Individualized⁵.

Therapy sequencing

Starting point	Preferred order	Branch point / evidence boundary
Cisplatin-eligible, resectable MIBC	Neoadjuvant durvalumab plus GC ×4 → cystectomy → adjuvant durvalumab ×8, or perioperative EV plus pembrolizumab → cystectomy → postoperative EV plus pembrolizumab²³.	NIAGARA and EV-304 are distinct perioperative strategies; their results do not establish a sequence of one regimen after the other²³.
Cisplatin-ineligible or declining cisplatin	EV plus pembrolizumab ×3 → cystectomy → postoperative EV plus pembrolizumab¹.	EV-303 directly studied this population and this full perioperative sequence¹.
New obstruction or borderline renal function	Relieve obstruction when feasible → restage renal function and cisplatin eligibility → choose the perioperative pathway⁵⁶.	This is a pretreatment decision step, not evidence that a pre-drainage creatinine permanently determines eligibility⁵⁶.
Not a cystectomy candidate or declining cystectomy	Refer to a bladder-preservation pathway rather than applying perioperative-trial efficacy estimates⁵⁷.	The listed phase 3 regimens are cystectomy-anchored and do not establish a bladder-preservation sequence¹²³.

Surveillance and treatment de-escalation

Post-cystectomy imaging schedule (EAU practice framework)

Time after cystectomy	Chest/abdomen/pelvis CT (incl. upper tract when indicated)⁶	Notes⁶
Every 6 months through 36 months⁶	CT⁶	Panel framework; intensify upper-tract monitoring if multifocal disease, CIS, or positive ureteral margins⁶
Annually thereafter through ~60 months⁶	CT⁶	Consider stopping routine CT after 5 years in majority of patients without ongoing high-risk features⁶

Phase	Monitoring cadence	Stop, hold, or de-escalate	Re-escalation / next line
Perioperative EV/pembro or durvalumab/GC	Restage renal function after obstruction relief; labs each cycle; neuropathy and glucose monitoring on EV; immune-symptom review⁴⁵.	Complete neoadjuvant cycles before cystectomy when feasible; complete protocol-defined adjuvant doses (durvalumab ×8 post-op; EV/pembro per EV-303/304)¹²³. Hold for toxicity per label⁴.	Residual ypT2–4 or ypN+ after perioperative therapy → adjuvant urothelial page if no prior ICI completion; recurrence → mUC page⁵⁶.

Cystectomy remains the anchor; perioperative trials are not evidence for bladder preservation without a separate pathway⁵⁷.
Stop systemic therapy at planned perioperative completion; surveillance thereafter follows the EAU CT schedule above⁵⁶.

Perioperative MIBC 2-year EFS published landmarks

Published 2-year EFS landmarks only across EV-303, EV-304, and NIAGARA; not head-to-head; not reconstructed KM curves¹²³.

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
EV-303 / KEYNOTE-905, N=344	Cisplatin-ineligible or declining MIBC planned for RC+PLND¹	Neoadjuvant EV 1.25 mg/kg days 1,8 plus pembrolizumab 200 mg every 3 weeks ×3 → RC+PLND → adjuvant EV ×6 plus pembrolizumab¹	RC+PLND alone¹	Event-free survival¹	Two-year EFS 74.7% vs 39.4%; two-year OS 79.7% vs 63.1%; EFS HR 0.40; OS HR 0.50¹.	Specific cisplatin-ineligible/declining population; perioperative, not adjuvant-only, strategy¹.
EV-304 / KEYNOTE-B15, N=808	Cisplatin-eligible MIBC²	Neoadjuvant EV plus pembrolizumab ×4 → RC+PLND → adjuvant EV plus pembrolizumab²	Neoadjuvant GC ×4 → RC+PLND²	Event-free survival²	Two-year EFS 79.4% vs 66.2%; two-year OS 86.9% vs 81.3%; EFS HR 0.53; OS HR 0.65².	Comparator is neoadjuvant GC, not surgery alone².
NIAGARA, N=1,063	Cisplatin-eligible MIBC³	Neoadjuvant durvalumab plus GC ×4 → RC → adjuvant durvalumab ×8³	Neoadjuvant GC ×4 → RC³	Event-free survival³	24-month EFS 67.8% vs 59.8%; 24-month OS 82.2% vs 75.2%; EFS HR 0.68; OS HR 0.75³.	Perioperative anti-PD-L1 strategy; does not isolate the contribution of neoadjuvant versus adjuvant durvalumab³.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
Cisplatin eligibility	Regimen-selection factor between NIAGARA / EV-304 and EV-303 pathways¹²³⁵⁶	Reassessment after obstruction relief⁵⁶	Determines whether GC-containing or cisplatin-ineligible perioperative packages apply¹²³.	Do not infer eligibility from one pre-drainage creatinine alone⁵⁶.
Histology / variant	Pathology review and multidisciplinary planning⁵⁷	Variant-specific perioperative analyses⁵⁷	Flags need for expert review; does not auto-select EV/ICI or GC⁵⁷.	Variant-specific efficacy for these newer perioperative regimens was not established in the retrieved trials¹²³.
PD-L1	Not a selector for perioperative EV plus pembrolizumab or NIAGARA in the retrieved reports¹²³	Exploratory correlatives in ICI trials⁵	Does not choose among EV-303, EV-304, and NIAGARA on this page¹²³.	No validated perioperative threshold in these sources¹²³.
ctDNA	Not standard for selecting neoadjuvant treatment⁵	Investigational MRD / perioperative correlatives⁵	Do not use it to omit curative-intent local therapy outside a protocol⁵⁶.	Assay decision thresholds are not practice-ready for neoadjuvant selection here⁵.
Nectin-4 / HER2 / FGFR	Not selectors for perioperative EV/ICI in EV-303, EV-304, or NIAGARA¹²³	Metastatic biomarker-directed options after recurrence⁵	No change to perioperative regimen choice in these trials¹²³.	Do not require Nectin-4/HER2/FGFR positivity to offer labeled perioperative EV plus pembrolizumab¹²⁴.

Upcoming research

Field direction: perioperative EV plus pembrolizumab and durvalumab plus GC are now practice standards; longer follow-up and completion rates will refine durability counseling¹²³.

Trial or publication	Why it may change care	Evidence status
EV-304 / KEYNOTE-B15 longer follow-up	Clarifies durability and postoperative treatment completion for a perioperative EV plus pembrolizumab strategy against GC².	Peer-reviewed report; continued follow-up².
NIAGARA longer follow-up	Clarifies durability of the perioperative durvalumab plus GC result³.	Peer-reviewed phase 3 report; continued follow-up³.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Perioperative EV plus pembrolizumab, EV-303	Grade ≥3 AEs 71.3% vs 45.9%¹.	Named-event percentages were not extracted from the retrieved primary source set¹.	Promptly report rash, neuropathy, vision changes, thirst/polyuria, or immune-toxicity symptoms; assess postoperative recovery before adjuvant dosing¹⁴.
Perioperative EV plus pembrolizumab, EV-304	Grade ≥3 AEs 75.7% vs 67.2%².	Named-event percentages were not extracted from the retrieved primary source set².	Use the same EV and immune-toxicity counseling; monitor cumulative neuropathy and glycemic symptoms²⁴.
Perioperative durvalumab plus GC, NIAGARA	Grade 3–4 treatment-related AEs 40.6% vs 40.9%³.	Named-event percentages were not extracted from the retrieved primary source set³.	Review cytopenic infection, renal function, neuropathy, and immune toxicity; severe symptoms require urgent assessment³.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and available rate	Patient action / clinic response
Perioperative EV plus pembrolizumab, EV-303	FDA label treatment-arm rates (single-arm label rates; no paired comparator % in the retained label table): rash 54%, grade 3–4 7%; peripheral neuropathy 39%, grade 3–4 3%; increased glucose 72%, grade 3–4 12%; increased creatinine 47%, grade 3–4 8%⁴. Trial-level grade ≥3 AEs 71.3% vs 45.9% with RC+PLND alone¹.	Check neuropathy, skin, glucose, renal function, visual symptoms, and immune-mediated bowel, lung, liver, and endocrine symptoms before each treatment; new numbness/weakness, thirst/polyuria, rash, vision change, dyspnea, or persistent diarrhea requires prompt contact and a pre-dose assessment⁴.
Perioperative EV plus pembrolizumab, EV-304	FDA label treatment-arm rates (single-arm label rates; no paired comparator % in the retained label table): rash 63%, grade 3–4 12%; peripheral neuropathy 43%, grade 3–4 3%; hyperglycemia 20%, grade 3–4 7%; dry eye 25%, no grade 3–4 event; increased creatinine 49%, grade 3–4 8%⁴. Trial-level grade ≥3 AEs 75.7% vs 67.2% with neoadjuvant GC².	Use the same EV and immune monitoring; focus on cumulative neuropathy, glucose, renal function, and visual symptoms before postoperative doses⁴.
Perioperative durvalumab plus GC, NIAGARA	Grade 3–4 treatment-related AEs 40.6% vs 40.9%; a comparable named monitoring rate was not extracted from the retrieved primary source set³.	Check CBC, renal function, electrolyte replacement needs, neuropathy/hearing symptoms, and immune-mediated bowel, lung, liver, and endocrine symptoms. Fever, infection symptoms, dyspnea, severe diarrhea, or reduced urine output needs urgent assessment³.

Epic phrase

#neoadjuvantmibc

Counseling: EV-303 perioperative EV/pembro in cisplatin-ineligible MIBC: 2-year event-free survival about 75% vs 39% with RC+PLND alone (EFS HR 0.40 vs surgery alone); 2-year OS about 80% vs 63% with RC+PLND alone (OS HR 0.50). EV-304 cisplatin-eligible: 2-year EFS 79.4% vs 66.2% with neoadjuvant GC (HR 0.53 vs GC). NIAGARA durvalumab plus GC: 24-month EFS 67.8% vs 59.8% with neoadjuvant GC alone (HR 0.68 vs GC); 24-month OS 82.2% vs 75.2% with GC alone (HR 0.75). Regimens are distinct perioperative packages, not sequential.
Counseling: Reviewed surveillance and de-escalation: complete neoadjuvant then cystectomy then protocol adjuvant doses; post-cystectomy chest/abdomen/pelvis CT every 6 months through 36 months then annually through ~60 months (EAU framework); stop systemic therapy at planned perioperative completion; recurrence → adjuvant page if residual high-risk without prior ICI completion, or metastatic pathway.
Counseling: Reviewed treatment order: cisplatin-eligible patients may receive perioperative durvalumab plus GC or perioperative EV plus pembrolizumab → cystectomy → the regimen's specified postoperative treatment; cisplatin-ineligible/declining patients have EV-303 support for EV plus pembrolizumab → cystectomy → postoperative EV plus pembrolizumab. These are distinct perioperative strategies, not sequential regimens. ***
Monitoring: For EV plus pembrolizumab, review numbness/weakness, rash, vision changes, thirst/polyuria, creatinine, and immune symptoms before each dose. The FDA label reports EV-303 treatment-arm rates (single-arm label rates; no paired comparator % in the retained label table): neuropathy 39%, rash 54%, and increased glucose 72%; EV-304 treatment-arm rates: neuropathy 43%, rash 63%, and hyperglycemia 20%. Trial-level grade ≥3 AEs were 71.3% vs 45.9% with RC+PLND alone (EV-303) and 75.7% vs 67.2% with neoadjuvant GC (EV-304). For durvalumab plus GC, monitor CBC, renal function, electrolytes, neuropathy/hearing, and immune symptoms; NIAGARA grade 3–4 TRAEs 40.6% vs 40.9% with GC alone. Promptly report rash, numbness/weakness, vision changes, thirst/polyuria, cough/dyspnea, diarrhea, fever, or other concerning treatment effects. ***
Decision: *** selects perioperative EV plus pembrolizumab / perioperative durvalumab plus GC / another cystectomy-anchored plan / bladder-preservation evaluation.
Labs/NGS: CBC, CMP, renal function, glucose, baseline neuropathy/hearing assessment ***.
Procedures: *** urinary obstruction relief, restaging, cystectomy/PLND planning, and multidisciplinary review.
Follow-up: *** toxicity review, surgical timing, and postoperative treatment planning.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Replaced post-cystectomy surveillance with EAU CT every 6 months ×3 years then annual through ~60 months; added perioperative 2-year EFS landmark figure; expanded Biomarkers to five-column table; mirrored EAU cadence in paired dotphrase.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Labeled FDA monitoring rates as single-arm label rates and restated trial-level grade ≥3 AEs with named comparators; mirrored comparator-named counseling in the paired dotphrase.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added FDA-label EV-303 and EV-304 named monitoring rates without transferring metastatic rates into the perioperative setting.
2026-09-21: Added cystectomy-anchored therapy sequencing and all-regimen on-treatment monitoring.
2026-09-21: Created resectable MIBC neoadjuvant/perioperative setting page with source-linked phase 3 evidence.

Edit evidence markdown

Evidence page